Crossmark

Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand–foot skin reactions in sorafenib-treated patients

Crossref DOI link: https://doi.org/10.1007/s00280-018-3655-z

Published Online: 2018-07-30

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Saito, Kosuke

Ikeda, Masafumi

Kojima, Yasushi

Hosoi, Hiroko

Saito, Yoshiro

Kondo, Shunsuke https://orcid.org/0000-0001-9565-117X
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development (Grant Number 17mk0101045j0303, Grant Number 17ak0101043j0603)

Bayer Yakuhin, Ltd
License Information

Text and Data Mining valid from 2018-07-30

Version of Record valid from 2018-07-30
More Information

Article History

Received: 11 April 2018

Accepted: 23 July 2018

First Online: 30 July 2018

Compliance with ethical standards

:

: Shunsuke Kondo has received research funding from AstraZeneca, Eli Lilly Japan K.K., ASLAN, Pfizer, Takeda Yakuhin, Ltd., and Bayer Yakuhin, Ltd. None of the other authors have potential conflicts of interest to declare.

Document is current

Any future updates will be listed below